TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15147122
Drug: GM-CSF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (300 microg) + recombinant hepatitis B vaccine (40 microg)
Study: 15147122
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: recombinant hepatitis B vaccine (40 microg)
Study: 9053413
Drug: Herbal eye
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal eye drop preparation
Study: 2874047
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with ipratropium bromide (two inhalations four times daily, 20 micrograms per inhalation) in combination with oral terbutaline and aerosolized salbutamol
Study: 2874047
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide treatment
Study: 28911067
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus bevacizumab (CAP-B) maintenance treatment
Study: 16756416
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TN) 0 mg
Study: 16756416
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TN) 7 mg
Study: 18489014
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TN) 14 mg
Study: 16756416
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TN) 21 mg
Study: 15007373
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TN)
Study: 9362437
Drug: Pamidronate (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (120 mg, 2-hour infusion)
Study: 1328567
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg once a day) for 8 days
Study: 1328567
Drug: Hydralazine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (5 mg/day) and Captopril (25 mg/day) for 6 weeks
Study: 1328567
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg once a day) and Nitrendipine (20 mg once a day)
Study: 3900591
Drug: Melphalan plus
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan plus Prednisone (M.P.) X 6 monthly cycles
Study: 3900591
Drug: Vincristine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine plus Melphalan plus Cyclophosphamide plus Prednisone (VMCP) X 6 monthly cycles
Study: 29169840
Drug: Alfaxalone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (2 mg kg−1) with fentanyl (2 μg kg−1) for induction and alfaxalone variable rate infusion (VRI) combined with fentanyl constant rate infusion (CRI) (10 μg kg−1 hour−1) for maintenance (group AF)
Study: 29169840
Drug: Alfaxalone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (2 mg kg−1) for induction and alfaxalone variable rate infusion (VRI) (0.15 mg kg−1 minute−1) for maintenance (group AP)
Study: 24063556
Drug: Treatment-As-Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-As-Usual
Study: 19587126
Drug: Low-fat, high-fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-fruit and -vegetable diets (mean intake: 6.1 servings/d of fruits and vegetables, 2.7 mg/d of lutein and zeaxanthin)
Study: 19587126
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (standard diet, mean intake: 4.6 servings/d of fruits and vegetables, 2.1 mg/d of lutein and zeaxanthin)
Study: 19587126
Drug: High intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intake of lutein and zeaxanthin (highest quintile, median 6.4 mg/d)
Study: 11889149
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RLX) 60 mg/d
Study: 11589267
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RLX) 120 mg/d
Study: 11589267
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RLX) 60 mg/d in women with BMI >26.4 kg/m2
Study: 11589267
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RLX) 120 mg/d in women with BMI >26.4 kg/m2
Study: 9846035
Drug: Ondansetron (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (chronic treatment)
Study: 9846035
Drug: Placebo (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (acute treatment)
Study: 9846035
Drug: Placebo (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (chronic treatment)
Study: 9337187
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of bupivacaine (TEA, Th1 to Th5)
Study: 9337187
Drug: Standard anti‐anginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti‐anginal therapy (control group)
Study: 7945741
Drug: Biperiden, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden, 4 mg
Study: 7945741
Drug: Bornaprine, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprine, 4 mg
Study: 2979234
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg kg‐1 h‐1 ranitidine
Study: 2979234
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg kg‐1 h‐1 ranitidine
Study: 19380382
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (6 mg)
Study: 28960312
Drug: Immediate-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release niacin (2 g) with high-fat meals containing saturated fatty acids (SFAs)
Study: 28960312
Drug: Immediate-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release niacin (2 g) with high-fat meals containing monounsaturated fatty acids (MUFAs)
Study: 28960312
Drug: Immediate-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release niacin (2 g) with high-fat meals containing MUFAs plus omega-3 long-chain polyunsaturated fatty acids (LCPUFAs)
Study: 28960312
Drug: Immediate-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release niacin (2 g) with high-fat meals containing no fat
Study: 28386699
Drug: LSD (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (100 mcg orally)
Study: 26175218
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1-3 ml) used for sealing the needle track (Group B)
Study: 12544181
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg methylphenidate
Study: 13680085
Drug: 0.30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/kg methylphenidate
Study: 12544181
Drug: 0.60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.60 mg/kg methylphenidate
Study: 9187188
Drug: Flow triggering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow triggering of 5/2 L/min
Study: 9187188
Drug: Flow triggering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow triggering of 10/3 L/min
Study: 8068446
Drug: Clodronate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (300 mg/daily for 5 days)
Study: 8068446
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/daily for 5 days) after clodronate in 7 relapsing patients
Study: 8068446
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/daily for 5 days) in 8 newly diagnosed patients
Study: 3195851
Drug: CDP-choline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline (100 mg/kg/day for seven days)
Study: 8836
Drug: Benorylate suspension
Normalized name: benorilate Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benorylate suspension for 7 days
Study: 31186120
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (14 mg, once daily)
Study: 31186120
Drug: Subcutaneous liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous liraglutide (1.8 mg, once daily)
Study: 28513068
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for 12 weeks
Study: 28513068
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for 12 weeks
Study: 19480610
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine medicated plaster and pregabalin combination therapy
Study: 19480610
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine medicated plaster monotherapy
Study: 19480610
Drug: Pregabalin monotherapy
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin monotherapy
Study: 19480610
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine medicated plaster with continued pregabalin treatment
Study: 7726317
Drug: Fluphenazine 10
Normalized name: fluphenazine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine 10 mg/day
Study: 7726317
Drug: Fluphenazine 20
Normalized name: fluphenazine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine 20 mg/day
Study: 7726317
Drug: Fluphenazine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine 30 mg/day
Study: 7726317
Drug: Fluphenazine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine (all doses)
Study: 7262795
Drug: Daily interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interval therapy (alternating application of Jellin ointment or cream and their bases, n = 26)
Study: 7262795
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (application of Jellin ointment or cream alone, n = 24)
Study: 7262795
Drug: Weekly interval
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly interval therapy (application of Jellin ointment or cream for 4 days followed by 3 days of the corresponding base, n = 21)
Study: 7262795
Drug: Daily interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interval therapy
Study: 7262795
Drug: Interval therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval therapy
Study: 30845322
Drug: Typhoid conjugate
Normalized name: Typhoid conjugate vaccine (TCV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid conjugate vaccine campaign
Study: 9923411
Drug: rhIL-11 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 (both doses)
Study: 776197
Drug: Subanaesthetic incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanaesthetic incremental doses of Althesin
Study: 776197
Drug: Single sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single sedative dose of diazepam
Study: 30641027
Drug: Indacaterol/Glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/Glycopyrronium (IND/GLY) 110/50 μg once daily for 14 days
Study: 25593053
Drug: Transendocardial stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendocardial stem cell injection (TESI) using culture‐expanded mesenchymal stem cells (MSCs)
Study: 19527481
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart (BIAsp) three times a day (70/30 high-mix before breakfast and lunch, 30/70 before dinner)
Study: 19527481
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart (BIAsp) three times a day
Study: 19527481
Drug: Biphasic human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic human insulin (BHI) 30/70 twice a day
Study: 14993632
Drug: Multi-dose DEC
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose DEC (6 mg/kg) and Alb (400 mg) for seven days
Study: 14993632
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with single-dose DEC/Alb 12 months after first treatment
Study: 11207085
Drug: 3.4 g
Normalized name: psyllium 3.4 g oral wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g of omega-3 fatty acids daily
Study: 8422853
Drug: Carbamazepine 600
Normalized name: carbamazepine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 600 mg
Study: 24417206
Drug: Carbamazepine 400
Normalized name: carbamazepine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 400 mg
Study: 17161535
Drug: Lamotrigine 300
Normalized name: lamotrigine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 300 mg
Study: 3009634
Drug: RRV-1 vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-1 vaccine
Study: 6143964
Drug: RIT 4237
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4237 vaccine
Study: 15069129
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection
Study: 29858113
Drug: Tight-control treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight-control treatment aiming at SDAI ≤ 3.3
Study: 29858113
Drug: Tight-control treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight-control treatment aiming at DAS28-CRP < 2.6
Study: 27487966
Drug: Nurse-initiated antiviral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nurse-initiated antiviral therapy with pegylated interferon and ribavirin
Study: 27487966
Drug: Physician-initiated antiviral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Physician-initiated antiviral therapy with pegylated interferon and ribavirin
Study: 24759852
Drug: Family-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive behavior therapy (FB-CBT) including exposure plus response prevention
Study: 24759852
Drug: FB relaxation
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FB relaxation treatment (FB-RT)
Study: 23159875
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral mecamylamine
Study: 17553503
Drug: Massaging with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massaging with dimethyl sulfoxide (DMSO) cream
Study: 17553503
Drug: Massaging with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massaging with an indifferent cream
Study: 12017395
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg
Study: 11560018
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atenolol and enalapril maleate
Study: 11560018
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atenolol, enalapril maleate, and hydrochlorothiazide
Study: 8167121
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin solution
Study: 8167121
Drug: Buffered cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered cold cardioplegic solution
Study: 6449205
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g mezlocillin/oxacillin (20% solution) injected intramuscularly
Study: 6449205
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g mezlocillin/oxacillin (25% aqueous solution) injected intramuscularly t.i.d. for about 7 days
Study: 31641754
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ivermectin, diethylcarbamazine, and albendazole (IDA)
Study: 31641754
Drug: 3 annual
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 annual doses of ivermectin and albendazole (IA)
Study: 31641754
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of IDA
Study: 28125621
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (viewing a video featuring individuals living in extreme poverty)
Study: 21120562
Drug: 5 mCi
Normalized name: iobenguane I-131 15 MCI/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mCi Yttrium-90 plus 40 mg of triamcinolone hexacetonide (Y/TH Group)
Study: 21120562
Drug: 15 mCi
Normalized name: iobenguane I-131 15 MCI/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mCi Samarium-153 hydroxyapatite plus 40 mg of triamcinolone hexacetonide (Sm/TH Group)
Study: 21120562
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone hexacetonide alone (Control Group)
Study: 19668094
Drug: Captain's Log
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captain's Log cognitive training software (8 weeks, weekly sessions)
Study: 10048504
Drug: Irbesartan 75
Normalized name: irbesartan 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 75 mg once daily (doubled at week 6 if seated diastolic blood pressure >= 90 mmHg)
Study: 2923821
Drug: Ethanol (95%‐0.84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (95%‐0.84 ml/kg)
Study: 29033138
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg daily) - overt group
Study: 25528758
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation antipsychotics
Study: 20058592
Drug: Intradiscal methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal methylene blue (MB) injection
Study: 17264356
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (vacuum-assisted closure)
Study: 3356049
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of epidural bupivacaine-fentanyl (initial dose of 5-7 ml, continuous infusion of 3 ml/h)
Study: 3356049
Drug: Repeated injections
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated injections of epidural bupivacaine-fentanyl (initial dose ranged from 8-12 ml)
Study: 29434529
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (≥2.2 g/kg/d)
Study: 22192511
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/day
Study: 18481712
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment within 1 month after operation
Study: 18481712
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment within 2 weeks after attack
Study: 14637261
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy + atorvastatin (10 mg/day), Group B
Study: 14637261
Drug: Conventional therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy, Group A
Study: 14637261
Drug: Atorvastatin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (in vitro, 0.1-10 micromol/l)
Study: 10718567
Drug: Implicit learning
Normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Implicit learning (concurrent secondary tone-counting task)
Study: 8258205
Drug: Amoxicillin 40
Normalized name: amoxicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 40 mg/kg/day for 10 days (Group I: one total dose of amoxicillin and two doses of placebo daily)
Study: 8258205
Drug: Amoxicillin 40
Normalized name: amoxicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 40 mg/kg/day for 10 days (Group II: three divided doses of amoxicillin daily)
Study: 3896354
Drug: Masker treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masker treatment
Study: 3896354
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no instrumental treatment
Study: 3896354
Drug: Hearing aid
Normalized name: hearing aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearing aid or combination instrument treatment
Study: 23131884
Drug: Acamprosate (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (2000 mg/d)
Study: 10561343
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy
Study: 26287955
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy